These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 3167841

  • 1. Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity.
    Lichtenstein A, Spina C, Berek JS, Jung T, Zighelboim J.
    Cancer Res; 1988 Oct 15; 48(20):5853-9. PubMed ID: 3167841
    [Abstract] [Full Text] [Related]

  • 2. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
    Shau H, Isacescu V, Ibayashi Y, Tokuda Y, Golub SH, Fahey JL, Sarna GP.
    J Biol Response Mod; 1990 Feb 15; 9(1):71-80. PubMed ID: 2319261
    [Abstract] [Full Text] [Related]

  • 3. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
    Karavodin LM, Golub SH.
    Nat Immun Cell Growth Regul; 1990 Feb 15; 3(4):193-202. PubMed ID: 6241293
    [Abstract] [Full Text] [Related]

  • 4. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
    Koren HS, Brandt CP, Tso CY, Laszlo J.
    J Biol Response Mod; 1983 Feb 15; 2(2):151-65. PubMed ID: 6644332
    [Abstract] [Full Text] [Related]

  • 5. Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
    Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD.
    Cancer Treat Rev; 1985 Dec 15; 12 Suppl B():23-32. PubMed ID: 3833327
    [Abstract] [Full Text] [Related]

  • 6. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J, Greene T, Ettinger LM, Lagasse LD.
    Cancer Res; 1985 Sep 15; 45(9):4447-53. PubMed ID: 4028027
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
    Bonavida B, Lebow LT, Bradley TP.
    J Immunol; 1984 Feb 15; 132(2):594-8. PubMed ID: 6606675
    [Abstract] [Full Text] [Related]

  • 8. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 15; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 9. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer.
    Berek JS, Bast RC, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, Knapp RC, Zighelboim J.
    Obstet Gynecol; 1984 Nov 15; 64(5):708-14. PubMed ID: 6493663
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity.
    Katz JD, Mitsuyasu R, Gottlieb MS, Lebow LT, Bonavida B.
    J Immunol; 1987 Jul 01; 139(1):55-60. PubMed ID: 3584988
    [Abstract] [Full Text] [Related]

  • 11. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E, Eisenthal A, Sachs D, Rosenberg SA.
    J Immunol; 1987 Mar 15; 138(6):1992-8. PubMed ID: 3493293
    [Abstract] [Full Text] [Related]

  • 12. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
    Edwards BS, Hawkins MJ, Borden EC.
    Cancer Res; 1984 Jul 15; 44(7):3135-9. PubMed ID: 6586292
    [Abstract] [Full Text] [Related]

  • 13. Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer.
    Lichtenstein AK, Berek J, Zighelboim J.
    J Natl Cancer Inst; 1985 Feb 15; 74(2):349-55. PubMed ID: 3856049
    [Abstract] [Full Text] [Related]

  • 14. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
    Allavena P, Introna M, Sessa C, Mangioni C, Mantovani A.
    J Natl Cancer Inst; 1982 Apr 15; 68(4):555-62. PubMed ID: 6175786
    [Abstract] [Full Text] [Related]

  • 15. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients.
    Brenner BG, McCrea EL, Margolese RG.
    Anticancer Res; 1988 Apr 15; 8(4):653-8. PubMed ID: 3263077
    [Abstract] [Full Text] [Related]

  • 16. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E, Savary CA, Quesada JR, Gutterman JU, Hersh EM.
    J Natl Cancer Inst; 1983 Nov 15; 71(5):903-10. PubMed ID: 6580490
    [Abstract] [Full Text] [Related]

  • 17. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
    Fujimiya Y, Wagner RJ, Groveman S, Sielaff K, Kohsaka T, Nakayama M.
    Ther Immunol; 1995 Feb 15; 2(1):15-22. PubMed ID: 7553067
    [Abstract] [Full Text] [Related]

  • 18. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens.
    Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF.
    J Immunol; 1983 Oct 15; 131(4):1789-96. PubMed ID: 6225799
    [Abstract] [Full Text] [Related]

  • 19. Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.
    Weil-Hillman G, Hank JA, Rosenthal NS, Sondel PM.
    J Biol Response Mod; 1988 Oct 15; 7(5):424-37. PubMed ID: 3053997
    [Abstract] [Full Text] [Related]

  • 20. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
    Hersey P, Coates A, Rallings M, Hall C, MacDonald M, Spurling A, Edwards A, McCarthy WH, Milton GW.
    J Biol Response Mod; 1986 Jun 15; 5(3):236-49. PubMed ID: 3487622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.